ABBV News and Press, AbbVie Inc. From 06/25/24

2024-06-25 04:31:00 ET If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (NYSE: ABBV) , Ares Capital (NASDAQ: ARCC) , and Realty Income (NYSE: O) have what it takes to delive...

2024-06-24 08:40:00 ET Summary FutureGen Biopharm (Beijing) out-licensed global rights for its next-gen TL1A antibody, a proposed therapy for inflammatory bowel disease, to AbbVie in a $1.7 billion agreement. Shanghai MabCare Therapeutics out-licensed global rights (ex-China) for ...

2024-06-23 12:49:01 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection S&P posts three-week win streak, but momentum stalls after hitting 5,500 points mark ...

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

2024-06-21 14:41:10 ET Summary Brukinsa, a BTK inhibitor by BeiGene, shows strong revenue growth amidst ongoing patent litigation with AbbVie. BeiGene's financial health appears stable, with a favorable current ratio and a cash runway extending into 2026. I recommend buying Be...

2024-06-20 23:47:38 ET Summary Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly boost Nektar's prospects (and share price), but Phas...

2024-06-20 16:40:55 ET Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing...

2024-06-20 13:00:43 ET Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is proj...

2024-06-20 10:30:00 ET June 20, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (Nasdaq:AEMD ), a medical therapeutic company f...

2024-06-20 09:27:33 ET On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ulcerative colitis. This approval is a significant milestone, ...